YAVNE, Israel , Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified Conference call begins today at 8:30 am ET   YAVNE, Israel , Aug.

YAVNE, Israel , Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second

Independent Data Monitoring Committee R ecommends C ontinuation of the Study with N o   C hanges to Study Sample Size No Safety Concerns Identified Full Study   Enrollment Expected by Year-End 2021; D ata R eadout E xpected in t he F irst H alf of 2022 YAVNE, Israel , July 28, 2021 (GLOBE NEWSWIRE)

Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel , July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for

Primary Endpoints Met with Highly Statistically Significant Results Compared with Standard-of-Care YAVNE, Israel , July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair

Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and   D iabetic F oot U lcers Interim Assessment of Ongoing U.S.   Phase II Adaptive Design Study in Venus Leg Ulcers Expected End of July 2021 YAVNE, Israel , July 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd.

Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy YAVNE, Israel , June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair

Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 YAVNE, Israel , June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and

Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel , June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical